Eli Lilly’s (LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK’s (GSK) antibiotic, Augmentin, a Reuters report said.
Citing a research firm Pharmarack, the report said that Mounjaro generated 1B rupees (approximately $11.38M) in sales last month, exceeding Augmentin’s sales of 800M rupees.
In terms of volume, however, Augmentin remains the leader, with 5.8M units sold in October, compared to just 85,000 units of Mounjaro, which is priced higher.
Mounjaro has seen its sales double since its launch in India in March. This growth occurred before the entry of Novo Nordisk’s Wegovy, which was introduced to the market in June.
Recently, Lilly partnered with Indian pharmaceutical company Cipla to market Mounjaro under a different brand name.